← Back
NeuroTrials.ai
Neurology Clinical Trial Database

MINT

Inebilizumab for the Treatment of Autoimmune Generalized Myasthenia Gravis

Year of Publication: 2025

Authors: James F. Howard Jr., MD; Renato Mantegazza, MD; Jing Jing Wang, ..., MD; and the MINT Trial Investigators

Journal: New England Journal of Medicine

Citation: N Engl J Med 2025;392:1353-1365

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2407624


Clinical Question

Does inebilizumab, a CD19+ B-cell–depleting monoclonal antibody, improve symptoms and function in patients with autoimmune generalized myasthenia gravis who are positive for anti–AChR or anti–MuSK antibodies compared with placebo?

Bottom Line

In patients with autoimmune generalized myasthenia gravis, inebilizumab significantly improved MG-ADL scores over 26 weeks compared with placebo, with a favorable safety profile and greater benefits in the AChR-antibody–positive subgroup.

Major Points

  • Methotrexate did not reduce prednisone use in generalized MG: minimal prednisone dose at 12 months 11.6mg (MTX) vs 13.0mg (placebo); P=NS.
  • 50 patients with generalized MG on prednisone. 12-month, double-blind, placebo-controlled.
  • MTX dose: 20 mg/week (oral). Steroid-sparing trial design.
  • Secondary endpoints (QMG, MG-ADL) also not significantly different.
  • Well tolerated: hepatotoxicity, cytopenias rare at 20mg/week.
  • Published Lancet Neurology 2011 (Pasnoor et al.). Largest RCT of MTX in MG at time.
  • Challenge: MG trials are difficult — high placebo response, variable natural history.
  • MTX widely used empirically in MG despite this negative trial — clinical experience suggests longer treatment may be needed.
  • Trial may have been underpowered (n=50) and too short (12 months) to detect steroid-sparing effect.
  • Published as negative but influenced clinical practice: MTX remains second/third-line option in MG.

Design

Study Type: Randomized, double-blind, placebo-controlled, phase 3 trial

Randomization: 1

Blinding: Participants, investigators, and study personnel blinded

Enrollment Period: June 2021 – April 2023

Follow-up Duration: 52 weeks

Centers: 88

Countries: Multiple countries (not specified in extracted text)

Sample Size: 208

Analysis: Mixed-model repeated-measures analysis; intention-to-treat population


Inclusion Criteria

  • Age ≥18 years
  • Diagnosis of autoimmune generalized myasthenia gravis
  • Positive for anti–AChR or anti–MuSK antibodies

Exclusion Criteria

  • History of thymoma requiring treatment within the past year
  • Receipt of B-cell–depleting therapy within 6 months before screening
  • Use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomization

Arms

FieldInebilizumabControl
InterventionIntravenous inebilizumab 300 mg on days 1 and 15; AChR-positive participants received an additional dose on day 183Matching intravenous placebo infusions
Duration52 weeks52 weeks

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Mean change from baseline in MG-ADL score at week 26Primary-2.3-4.0<0.001
QMG score change at week 26Secondary-3.1-5.4<0.001
Time to sustained ≥3-point improvement in MG-ADLSecondaryNot reachedMedian 12 weeksHR 1.8<0.001
Any adverse eventAdverse78%80%
Serious adverse eventsAdverse6%7%
Infusion-related reactionAdverse3%4%

Subgroup Analysis

Greater magnitude of benefit in AChR-antibody–positive patients; MuSK subgroup too small for definitive conclusions.


Criticisms

  • Short follow-up for long-term safety assessment
  • Small sample size for MuSK-antibody–positive subgroup limits subgroup conclusions
  • Exclusion of patients recently treated with other B-cell–depleting agents may limit generalizability

Funding

Sponsored by Horizon Therapeutics

Based on: MINT (New England Journal of Medicine, 2025)

Authors: James F. Howard Jr., MD; Renato Mantegazza, MD; Jing Jing Wang, ..., MD; and the MINT Trial Investigators

Citation: N Engl J Med 2025;392:1353-1365

Content summarized and formatted by NeuroTrials.ai.